Doaa G. M. Mahmoud

Doaa G. M. Mahmoud

Auto-generated profile, based on publicly available information

Doaa G. M. Mahmoud

Chemistry Department, Faculty of Science, Minia University, Minia, 61519, Egypt, minia.edu.eg

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Journal of Tropical Medicine
Verified
Journal Article
Open access
Mahmoud A. A. IbrahimMahmoud A. A. Ibrahim
Mahmoud A. A. Ibrahim
DMDoaa G. M. Mahmoud
Doaa G. M. Mahmoud
Sherif ElsayedSherif Elsayed
Sherif Elsayed
PAPeter Ayoub
Peter Ayoub
GMGamal Mekhemer
Gamal Mekhemer
TATarad Abalkhail
Tarad Abalkhail
As the second most deadly infectious disease worldwide after COVID‐19, tuberculosis (TB) remains a pressing global health issue, further aggravated by multidrug‐resistant TB (MDR‐TB) and extensively drug‐resistant TB (XDR‐TB) strains. There is an urgent need to identify new anti‐TB treatments and novel therapeutics to confront drug resistance. The decaprenylphosphoryl‐D‐ribose oxidase (DprE1) is an essential protein for the biosynthesis of the mycobacterial cell wall, and its inhibition features a promising antitubercular strategy. NPAtlas was utilized as a reference database, comprising natural products with confirmed biological effects. The aim of the current study is to identify and prioritize promising nitro‐containing natural products from the NPAtlas as potential covalent DprE1 inhibitors using advanced in silico approaches. Herein, the docking scores of 133 nitro‐containing NPAtlas compounds were assessed using a covalent docking technique. Thereafter, NPAtlas compounds with docking scores lower than PBTZ169 (calc. −7.8 kcal·mol −1 ) were subjected to molecular dynamics simulation (MDS), accompanied by binding energy estimations utilizing the MM‐GBSA approach. Based on MM‐GBSA//250 ns MDS, NPA011203, NPA013234, NPA016048, NPA012944, NPA001712, and NPA002823 demonstrated higher binding affinities against DprE1 with Δ G binding values of −75.6, −62.7, −61.6, −57.6, −54.8, and −50.7 kcal·mol −1 , respectively, than PBTZ169 (calc. −49.4 kcal·mol −1 ). The identified NPAtlas compounds also demonstrated structural and energetic stability within the DprE1 active site throughout 250 ns MDS. Physicochemical and ADMET predictions of the identified NPAtlas compounds indicated a suitable molecular size, favorable absorption, and negligible toxicity, suggesting their potential oral bioavailability. These in silico outcomes provide preliminary insights into the identified NPAtlas compounds as potential DprE1 inhibitors and can guide subsequent in vitro/in vivo experiments.

1 January 2026 in Journal of Chemistry
Verified
Journal Article
Open access
PDF file
Mahmoud A. A. IbrahimMahmoud A. A. Ibrahim
Mahmoud A. A. Ibrahim
DMDoaa G. M. Mahmoud
Doaa G. M. Mahmoud
PAPeter Ayoub
Peter Ayoub
YHYanshuo Han
Yanshuo Han
AAAlaa H. M. Abdelrahman
Alaa H. M. Abdelrahman
ARAhmed Rady
Ahmed Rady
Tuberculosis (TB), a malevolent bacterial scourge induced by Mycobacterium TB , continues to be a chief reason for morbidity and fatality all over the world. TB is becoming more of an issue due to antibiotic resistance to traditional medications. As a result, there is an increasing and pressing need for new medicines, a task that requires identifying viable drug targets. DprE1, an anti‐TB target, is responsible for mycobacterial cell wall synthesis. Inhibiting DprE1 activity effectively inhibits cell wall biosynthesis and shows great potential as an antitubercular strategy. Macozinone (PBTZ169), derived from the benzothiazinone (BTZ) scaffold, has been extensively investigated as a candidate irreversible covalent inhibitor targeting DprE1. In the current research endeavor, the binding scores of 230 drug candidates containing nitro groups at the investigational or clinical trial stage were evaluated against DprE1 using a covalent docking approach. Based on the available experimental data, the efficacy of the employed covalent docking technique in predicting the DprE1‐drug binding pose was primarily assessed. The drug candidates with binding scores less than macozinone (calc. −7.8 kcal/mol) underwent MD simulations (MDSs), accompanied by binding energy assessments employing the molecular mechanics–generalized Born surface area (MM‐GBSA) approach. In accordance with the MM‐GBSA//250 ns MDS, niludipine (DB09240), DB02051, azelnidipine (DB09230), and manidipine (DB09238) revealed greater binding affinity with Δ G binding values of −58.8, −53.5, −52.6, and −51.3, respectively, than macozinone (calc. −49.4 kcal/mol). Subsequent MD analyses demonstrated excellent conformational stability of the investigated drug candidates bound to DprE1 throughout the 250 ns simulation timeframe. Regarding physicochemical and ADMET characteristics, the four promising drug candidates were bioavailable orally. Generally, these outcomes revealed that niludipine, DB02051, azelnidipine, and manidipine are prospective anti‐TB drug candidates that merit further experimental assays.